- £185.59bn
- £204.68bn
- $54.07bn
- 85
- 18
- 86
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.41 | ||
| PEG Ratio (f) | 0.76 | ||
| EPS Growth (f) | 27.38% | ||
| Dividend Yield (f) | 2.07% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.61 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 30.66 | ||
| Price to Sales | 4.44 | ||
| EV to EBITDA | 16.72 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.35% | ||
| Return on Equity | 19.7% | ||
| Operating Margin | 20.04% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 26,617 | 37,417 | 44,351 | 45,811 | 54,073 | 58,046.04 | 61,674.03 | 17.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +27.14 | +46.76 | +27.45 | -3.46 | +56.97 | +69.34 | +13.67 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
Directors
- Leif Johansson NEC (69)
- Pascal Soriot CEO (61)
- Aradhana Sarin CFO (46)
- Jeffrey Pott CHO
- Katarina Ageborg EVP
- Jose Baselga EVP (60)
- Pam Cheng EVP (50)
- Ruud Dobber EVP
- David Fredrickson EVP
- Menelas Pangalos EVP
- Iskra Reic EVP
- Leon Wang EVP
- Adrian Kemp SEC
- Euan Ashley NED
- Diana Layfield NED
- Tony Mok NED
- Andreas Rummelt NED (64)
- Marcus Wallenberg NED (65)
- Philip Broadley NID
- Michel Demare NID (64)
- Deborah Eldracher NID (60)
- Sherilyn McCoy NID (62)
- Nazneen Rahman NID
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- June 17th, 1992
- Public Since
- September 21st, 2007
- No. of Shareholders
- 63,435
- No. of Employees
- 94,300
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 1,550,682,580
- Address
- 1 Francis Crick Avenue, CAMBRIDGE, CB2 0AA
- Web
- https://www.astrazeneca.com/
- Phone
- +44 2073045000
- Auditors
- PricewaterhouseCoopers LLP
Latest News for AZN
Upcoming Events for AZN
AstraZeneca PLC at Handelsbanken Life Science Innovation (Virtual)
Q3 2025 AstraZeneca PLC Earnings Release
Q4 2025 AstraZeneca PLC Earnings Release
Similar to AZN
Allergy Therapeutics
London Stock Exchange
Animalcare
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
CRISM' Therapeutics
London Stock Exchange
FAQ
As of Today at 19:24 UTC, shares in AstraZeneca are trading at 11,968.00p. This share price information is delayed by 15 minutes.
Shares in AstraZeneca last closed at 11,968.00p and the price had moved by -8.07% over the past 365 days. In terms of relative price strength the AstraZeneca share price has underperformed the FTSE All Share Index by -17.03% over the past year.
The overall consensus recommendation for AstraZeneca is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe AstraZeneca dividend yield is 1.95% based on the trailing twelve month period.
Last year, AstraZeneca paid a total dividend of $3.16, and it currently has a trailing dividend yield of 1.95%.Looking ahead, the next dividend pay date is 2025-09-08.
We do not have data on when AstraZeneca is to next pay dividends. The historic dividend yield on AstraZeneca shares is currently 1.95%.
To buy shares in AstraZeneca you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 11,968.00p, shares in AstraZeneca had a market capitalisation of £185.59bn.
Here are the trading details for AstraZeneca:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: AZN
Based on an overall assessment of its quality, value and momentum AstraZeneca is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in AstraZeneca is 13,177.04p. That is 10.1% above the last closing price of 11,968.00p.
Analysts covering AstraZeneca currently have a consensus Earnings Per Share (EPS) forecast of $9.06 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AstraZeneca. Over the past six months, its share price has underperformed the FTSE All Share Index by -5.07%.
As of the last closing price of 11,968.00p, shares in AstraZeneca were trading +10.38% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AstraZeneca PE ratio based on its reported earnings over the past 12 months is 16.41. The shares last closed at 11,968.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AstraZeneca's management team is headed by:
- Leif Johansson - NEC
- Pascal Soriot - CEO
- Aradhana Sarin - CFO
- Jeffrey Pott - CHO
- Katarina Ageborg - EVP
- Jose Baselga - EVP
- Pam Cheng - EVP
- Ruud Dobber - EVP
- David Fredrickson - EVP
- Menelas Pangalos - EVP
- Iskra Reic - EVP
- Leon Wang - EVP
- Adrian Kemp - SEC
- Euan Ashley - NED
- Diana Layfield - NED
- Tony Mok - NED
- Andreas Rummelt - NED
- Marcus Wallenberg - NED
- Philip Broadley - NID
- Michel Demare - NID
- Deborah Eldracher - NID
- Sherilyn McCoy - NID
- Nazneen Rahman - NID